Terapia antiretroviral de inibidores da protease contra Toxoplasma gondii

AUTOR(ES)

Monzote, Lianet, Rodríguez, Marta, Alfonso, Yenisey, Cox, Raymundo

FONTE

Rev. Inst. Med. trop. S. Paulo

DATA DE PUBLICAÇÃO

2013-02

RESUMO

The introduction of highly active antiretroviral therapy (HAART) has caused a marked reduction in the occurrence and severity of parasitic infections, including the toxoplasmic encephalitis (TE). These changes have been attributed to the restoration of cell-mediated immunity. This study was developed to examine the activity of six antiretroviral protease inhibitors (API) on Toxoplasma gondii tachyzoites. The six API showed anti-Toxoplasma activity, with IC50 value between 1.4 and 6.6 µg/mL. Further studies at the molecular level should be performed to clarify if the use of API could be beneficial or not for AIDS patients with TE.

Documentos Relacionados

• Ação in vitro de drogas antiparasitárias, especialmente artesunato, contra Toxoplasma gondii
• Desenvolvimento de um modelo de vacinação contra Toxoplasma gondii empregando adenovírus recombinante
• Serine Protease Inhibitors Block Invasion of Host Cells by Toxoplasma gondii
• Prevalência de anticorpos contra Toxoplasma gondii em ovinos no município de Uberlândia, MG
• Anticorpos contra Toxoplasma gondii em roedores e marsupiais da Mata Atlântica, estado de São Paulo, Brasil